Abstract
Positron Emission Tomography (PET) has the potential to improve efficacy of established and novel cancer therapies and to assist more rapid and rational progression of promising novel therapies into the clinic. This is due to PETs unrivalled sensitivity and ability to monitor the pharmacokinetics and pharmacodynamics of drugs and biochemicals radiolabelled with short -lived positron emitting radioisotopes. PET is a multidisciplinary science which employs chemists, biologists, mathematicial modellers, pharmacologists as well as clinicians. Clinical research questions in oncology determine the methodological challenges faced by these other disciplines. Within this context we focus on the developments of the radiolabelled compounds that have underpinned the clinical work in oncology for monitoring tumour and normal tissue pharmacokinetics, assessment of tumour response, cell proliferation, gene expression, hypoxia, multidrug resistance and status of receptors on tumours.
Keywords: Radiolabelled Tracers, Anticancer Drugs, Positron Emission Tomography pet, anti cancer therapy, anticancer angents, n dihmethylamino ethyl acridine carboxamide, temozolomide, f fdg, c thymidine, muti drug resistance mdr, hypoxia
Current Pharmaceutical Design
Title: Radiolabelled Tracers and Anticancer Drugs for Assessment of Therapeutic Efficacy Using PET
Volume: 7 Issue: 18
Author(s): Frank Brady, Sajinder K. Luthra, Gavin D. Brown, Safiye Osman, Eric Aboagye, Azeem Saleem and Patricia M. Price
Affiliation:
Keywords: Radiolabelled Tracers, Anticancer Drugs, Positron Emission Tomography pet, anti cancer therapy, anticancer angents, n dihmethylamino ethyl acridine carboxamide, temozolomide, f fdg, c thymidine, muti drug resistance mdr, hypoxia
Abstract: Positron Emission Tomography (PET) has the potential to improve efficacy of established and novel cancer therapies and to assist more rapid and rational progression of promising novel therapies into the clinic. This is due to PETs unrivalled sensitivity and ability to monitor the pharmacokinetics and pharmacodynamics of drugs and biochemicals radiolabelled with short -lived positron emitting radioisotopes. PET is a multidisciplinary science which employs chemists, biologists, mathematicial modellers, pharmacologists as well as clinicians. Clinical research questions in oncology determine the methodological challenges faced by these other disciplines. Within this context we focus on the developments of the radiolabelled compounds that have underpinned the clinical work in oncology for monitoring tumour and normal tissue pharmacokinetics, assessment of tumour response, cell proliferation, gene expression, hypoxia, multidrug resistance and status of receptors on tumours.
Export Options
About this article
Cite this article as:
Brady Frank, Luthra K. Sajinder, Brown D. Gavin, Osman Safiye, Aboagye Eric, Saleem Azeem and Price M. Patricia, Radiolabelled Tracers and Anticancer Drugs for Assessment of Therapeutic Efficacy Using PET, Current Pharmaceutical Design 2001; 7 (18) . https://dx.doi.org/10.2174/1381612013396907
DOI https://dx.doi.org/10.2174/1381612013396907 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Analysis of Simple Sequence Repeats in Mammalian Cell Cycle Genes
Recent Advances in DNA & Gene Sequences (Discontinued) Exploring the Molecular Function of PIN1 by Nuclear Magnetic Resonance
Current Protein & Peptide Science Patent Selections:
Current Biomarkers (Discontinued) Targeting Neuronal Nicotinic Receptors in Cancer: New Ligands and Potential Side-Effects
Recent Patents on Anti-Cancer Drug Discovery Caspase-Independent Pathways of Programmed Cell Death: The Unraveling of New Targets of Cancer Therapy?
Current Cancer Drug Targets Metabotropic Glutamate Receptor Dependent Cortical Plasticity in Chronic Pain
Current Neuropharmacology Targeting the Brain: Advances in Drug Delivery
Current Pharmaceutical Biotechnology “Cancer Antigen WT1 Protein-Derived Peptide”-Based Treatment of Cancer -Toward the Further Development
Current Medicinal Chemistry Phytometabolites Targeting the Warburg Effect in Cancer Cells: A Mechanistic Review
Current Drug Targets Regulation of MicroRNAs by Phytochemicals: A Promising Strategy for Cancer Chemoprevention
Current Cancer Drug Targets The Clinical and Immunological Features of Patients with Primary Antibody Deficiencies
Endocrine, Metabolic & Immune Disorders - Drug Targets Pivotal Role of the Interaction Between Herbal Medicines and Gut Microbiota on Disease Treatment
Current Drug Targets Unconventional Interaction Forces in Protein and Protein-ligand Systems and their Impacts to Drug Design
Current Topics in Medicinal Chemistry Main Isoflavones Found in Dietary Sources as Natural Anti-inflammatory Agents
Current Drug Targets Antitumor Activity and Structure-Activity Relationship of Diterpenoids with a Dehydroabietyl Skeleton
Combinatorial Chemistry & High Throughput Screening Transcriptional Regulation of Antimicrobial Host Defense Peptides
Current Protein & Peptide Science Molecular Insight into the Inhibitory Mechanism of Galangin Towards Human Cytochrome P450 1A2. A Modeling Study
Letters in Drug Design & Discovery Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review
Current Cancer Drug Targets Pharmacokinetic Mechanisms for Reduced Toxicity of Irinotecan by Coadministered Thalidomide
Current Drug Metabolism Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective
Current Medicinal Chemistry